Search research articles
Contact Us
Filters
Showing results (371-380 of 434) with videos related to
Page
of 44
Sort By:
JAMA Dermatology
|
February 26, 2025
Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis
April W Armstrong, Kathryn Lee, Danielle Yee, et al.
JAMA Dermatology
|
August 21, 2024
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial
April W Armstrong, Melinda Gooderham, Charles Lynde, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population
Jonathan Corren, Stanley J Szefler, Ellen Sher, et al.
Journal of the American Academy of Dermatology
|
July 12, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
April W Armstrong, Melinda Gooderham, Richard B Warren, et al.
The European Respiratory Journal
|
September 10, 2024
Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study
James D Chalmers, Michal Shteinberg, Marcus A Mall, et al.
The Journal of Dermatological Treatment
|
June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Neil J Korman, Richard B Warren, Jerry Bagel, et al.
Immunotherapy
|
May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary
April W Armstrong, Melinda Gooderham, Richard B Warren, et al.
JAMA Dermatology
|
January 24, 2024
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic Review
Lourdes M Pérez-Chada, Zachary H Hopkins, Deepak M W Balak, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
The Journal of Rheumatology. Supplement
|
June 3, 2019
Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting
Deepak R Jadon, Vinod Chandran, Alexis Ogdie, et al.
Page
of 44
Search research articles
Search
Showing results (371-380 of 434) with videos related to
Sort By:
Page
of 44
JAMA Dermatology
|
February 26, 2025
Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis
April W Armstrong, Kathryn Lee, Danielle Yee, et al.
JAMA Dermatology
|
August 21, 2024
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial
April W Armstrong, Melinda Gooderham, Charles Lynde, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
February 15, 2024
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population
Jonathan Corren, Stanley J Szefler, Ellen Sher, et al.
Journal of the American Academy of Dermatology
|
July 12, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
April W Armstrong, Melinda Gooderham, Richard B Warren, et al.
The European Respiratory Journal
|
September 10, 2024
Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study
James D Chalmers, Michal Shteinberg, Marcus A Mall, et al.
The Journal of Dermatological Treatment
|
June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Neil J Korman, Richard B Warren, Jerry Bagel, et al.
Immunotherapy
|
May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary
April W Armstrong, Melinda Gooderham, Richard B Warren, et al.
JAMA Dermatology
|
January 24, 2024
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic Review
Lourdes M Pérez-Chada, Zachary H Hopkins, Deepak M W Balak, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
The Journal of Rheumatology. Supplement
|
June 3, 2019
Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting
Deepak R Jadon, Vinod Chandran, Alexis Ogdie, et al.
Page
of 44